Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 4.7 years of cash runway.
GLUE Financials Monte Rosa Therapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $124M | -$39M | 0.0% | -43.8% | -16.6% | -8.6% | -$27M | — | $130M |
| 2024 | $76M | -$73M | 0.0% | -107.3% | -32.6% | -16.6% | $38M | — | $224M |
| 2023 | $0 | -$135M | — | — | -75.5% | -44.6% | -$63M | — | $128M |
| 2022 | — | -$109M | — | — | -40.0% | -31.7% | -$105M | — | $55M |
| 2021 | — | -$74M | — | — | -21.3% | -20.2% | -$69M | — | $346M |
| 2020 | — | -$36M | — | — | 73.6% | -72.7% | -$26M | — | $42M |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $9M | -$43M | 0.0% | -547.8% | -8.9% | -6.3% | -$49M | — | $90M |
| Mar '26 | $4M | -$45M | 0.0% | -1188.5% | -8.5% | -6.0% | -$39M | — | $160M |
| Dec '25 | $3M | -$46M | 0.0% | -1787.7% | -19.8% | -10.3% | -$44M | — | $130M |
| Sep '25 | $13M | -$27M | 0.0% | -258.3% | -11.0% | -5.9% | $100M | — | $208M |
| Jun '25 | $23M | -$12M | 0.0% | -67.1% | -4.6% | -3.4% | -$36M | — | $69M |
| Mar '25 | $85M | $47M | 0.0% | 51.9% | 17.0% | 11.9% | -$47M | — | $79M |
| Dec '24 | $61M | $13M | 0.0% | 21.4% | 6.0% | 3.1% | $129M | — | $224M |
| Sep '24 | $9M | -$24M | 0.0% | -287.8% | -11.6% | -7.6% | -$21M | — | $126M |
| Jun '24 | $5M | -$30M | 0.0% | -695.3% | -13.5% | -8.8% | -$30M | — | $109M |
| Mar '24 | $1M | -$32M | 0.0% | -3284.5% | -21.0% | -12.0% | -$40M | — | $100M |
| Dec '23 | $0 | -$33M | — | — | -18.6% | -10.9% | $28M | — | $128M |
| Sep '23 | $0 | -$35M | — | — | -18.9% | -13.8% | -$26M | — | $59M |
| Jun '23 | $0 | -$35M | — | — | -16.5% | -12.6% | -$32M | — | $47M |
| Mar '23 | $0 | -$32M | — | — | -13.1% | -10.4% | -$33M | — | $52M |
| Dec '22 | — | -$31M | — | — | -11.3% | -9.0% | -$31M | — | $55M |
| Sep '22 | — | -$27M | — | — | -9.4% | -7.6% | -$22M | — | $112M |
| Jun '22 | — | -$26M | — | — | -8.8% | -7.3% | -$23M | — | $104M |
| Mar '22 | — | -$24M | — | — | -7.3% | -6.9% | -$29M | — | $138M |
| Dec '21 | — | -$23M | — | — | -6.7% | -6.4% | -$17M | — | $346M |
| Sep '21 | — | -$20M | — | — | -5.4% | -5.2% | -$20M | — | $367M |
Valuation over time
How the market has priced GLUE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 7.8× (Dec '24) to 9.9× (Sep '26).
P/S
Frequently asked questions
Is GLUE growing its revenue and profit?
See the revenue and net-income charts above for Monte Rosa Therapeutics, Inc.'s multi-year trend.
How much debt does GLUE have?
As of FY2025, Monte Rosa Therapeutics, Inc. reported — of total debt against $130M of cash.
What is GLUE's profit margin?
In FY2025, gross margin was —, operating margin -43.8%, and net margin -31.2%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.